Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias
Key facts
- Who runs it
- Lauren Moore
- Where
- Ann Arbor, Atlanta, Baltimore, Boston, Chicago, Dallas, Gainesville, Houston, Los Angeles, Minneapolis, New York, Philadelphia, San Francisco, Seattle, and Tampa, United StatesSee the 16 sitesAlso in 1 other country, 1 site
- Trial code
- Status
- Recruiting
- People taking part
- 1,400 people, planned
- Started
- Apr 2010
- Expected to end
- Dec 2030
- Type of study
- Observational, 3 groups
- Treatments tested
- Genetic Testing
- Blood Collection
- Magnetic Resonance Imaging (MRI) Scan
- Assessments and Questionnaires
- Cerebrospinal Fluid Collection
- Record updated
- 3 August 2026
Who can take part
- Age
- 6 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Affected individuals aged 6 or above with symptoms and/or signs of ataxia with genetic confirmation of SCA 1, 2, 3, 6, 7, 8, 10, 27B, or RFC1-ataxia either in themselves or first degree family member
- Any individual aged 18 or above with a definite molecular diagnosis of SCA 1, 2, 3, 6, 7, 8, 10, 27B, or RFC1-ataxia
- Former participants of the READISCA (NCT03487367) study
- Willingness to participate in the study and ability to give informed consent
- For MRI Sub-Study only: Previous READISCA enrollees; individuals aged 18 or above with a genetic confirmation of SCA1, 2, or 3 and a SARA score <10 at MRI pre-screening; Healthy control participants without neurological condition
Who cannot take part
- Exclusion of SCA 1, 2, 3, 6, 7, 8, 10, 27B, or RFC1-ataxia by previous DNA testing
- For MRI Sub-study only: Inability to undergo MRI scanning, pregnancy, and other neurological diseases than those of interest
- A lack of willingness to participate in the study
Where in United States
Also in 1 other country, 1 site
- University of MichiganAnn Arbor, United StatesContact: Frank FerrariTaking people
- Emory UniversityAtlanta, United StatesContact: Lorena BinghamTaking people
- John Hopkins UniversityBaltimore, United StatesContact: Vanessa NessporTaking people
- Harvard UniversityBoston, United StatesContact: Jason MacMoreTaking people
- Nortwestern UniversityChicago, United StatesContact: Karen WilliamsTaking people
- University of ChicagoChicago, United StatesContact: Laura P CrespoNo longer taking part
- University of Texas Southwestern Medical CenterDallas, United StatesContact: Sharon PrimeauxTaking people
- University of FloridaGainesville, United StatesContact: Amanda FessendenTaking people
- Houston MethodistHouston, United StatesContact: Noor AlbukhaleefahTaking people
- University of California, Los AngelesLos Angeles, United StatesContact: Westley UlitTaking people
- University of MinnesotaMinneapolis, United StatesContact: Laura P CrespoNo longer taking part
- Columbia UniversityNew York, United StatesContact: Nadia AmokraneTaking people
- University of PennsylvaniaPhiladelphia, United StatesContact: Anne Beckett-FedarkoTaking people
- University of California San FranciscoSan Francisco, United StatesContact: Zach LamsonTaking people
- University of WashingtonSeattle, United StatesContact: Sarah SimonTaking people
- University of South FloridaTampa, United StatesContact: Lucretia CampbellTaking people
About the trial
What the trial wants to find out
Spinocerebellar ataxias (SCA) are genetic neurological diseases that cause imbalance, poor coordination, and speech difficulties. There are different kinds of SCAs and this study will focus on types 1, 2, 3, 6, 7, 8, 10, 27B, and RFC1-ataxia (SCA 1, SCA 2, SCA 3, also known as Machado-Joseph disease, SCA 6, SCA 7, SCA 8, SCA 10, SCA27B, and RFC1-ataxia, also known as CANVAS). The diseases are rare, slowly progressive, cause increasingly severe neurological difficulties, and are variable across and within genotypes. The purpose of this research study is to bring together a group of experts in the field of SCA for the purpose of learning more about the disease.
Read full original descriptionShow less
The research questions are:
1. How do these diseases progress over time? 2. What are the best ways to measure the progression? 3. Do some genes, other than the gene that is abnormal in these diseases, have any effect on the way the disease behaves?
This is a nationwide study and the investigators expect that 1400 patients will participate all over North America. The participants will remain in the study for an indeterminate period of time, for as long as they are willing to participate. Study visits will be done every 12 months.
Within the broader CRC-SCA, there is an Imaging Sub-study aiming to identify magnetic resonance imaging (MRI) markers sensitive to the onset and progression of common SCAs. To accomplish this, participants attend annual visits involving a neurological exam, surveys, a blood draw, and an MRI scan. Participants can attend visits at one of three US locations - Minneapolis, MN; Gainesville, FL; or Dallas, TX and two European locations - Paris, France and Bonn, Germany. Eligible participants must either have SCA1, 2, or 3 or have been a participant of the previous READISCA study (NCT03487367). Gene-positive participants must have a SARA score less than 10; however, there is no SARA limit for participants previously enrolled in READISCA. All participants must be 18 years or older. Gene-negative participants should be 25-65 years old.
The 3 groups in the trial
- Participants with Spinocerebellar Ataxias (Main Study)
Individuals aged 6 or older with the spinocerebellar ataxias 1, 2, 3, 6, 7, 8, 10, 27b, or RFC1-Ataxia will be enrolled for genetic testing, blood collection, assessments, and questionnaires.
Treatment: Genetic Testing, Blood Collection, Assessments and Questionnaires, and Cerebrospinal Fluid Collection
- Participants with Spinocerebellar Ataxias (MRI Sub-study)
Adults with the spinocerebellar ataxias 1, 2, and 3 will be enrolled for genetic testing, blood collection, assessments, questionnaires, and magnetic resonance imaging (MRI).
Treatment: Genetic Testing, Blood Collection, Magnetic Resonance Imaging (MRI) Scan, and Assessments and Questionnaires
- Healthy Controls (MRI Sub-study)
Adults without spinocerebellar ataxias or other neurological conditions will be enrolled for genetic testing, blood collection, assessments, questionnaires, and magnetic resonance imaging (MRI).
Treatment: Genetic Testing, Blood Collection, Magnetic Resonance Imaging (MRI) Scan, and Assessments and Questionnaires
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical Research Consortium for the Study of Cerebellar Ataxias (CRC-SCA) for the Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias (SCA)
- Record updated
- 3 August 2026